An interventional study of Usual Care and Pulmonary Vein Isolation in Atrial Fibrillation (AF) and Mitral Valve (MV) Regurgitation, sponsored by Atrial Fibrillation Network. Not yet recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Atrial Fibrillation Network · Not applicable, Interventional, and Prevention
CABA-MiTRA-AFNET12 is a non-commercial, parallel-group, prospective, randomised, open, blinded endpoint assessment (PROBE), multi-centre, therapy strategy trial. The trial investigates patients with severe mitral valve regurgitation who have undergone transcatheter edge-to-edge mitral valve repair (M-TEER) and have concomitant atrial fibrillation (AF). The objective is to assess whether catheter ablation of AF is superior to standard-of-care treatment in patients after TEER in reduction of major adverse cardiovascular and cerebrovascular events (MACCE).
The occurrence of atrial fibrillation (AF) as the most frequent arrhythmia is associated with an increased risk of stroke, acute coronary syndrome, heart failure, and cardiovascular death. AF is often associated with mitral valve regurgitation (MR) which represents the most frequent valvular heart disease in an elderly population. Both entities are not only linked by a complex pathophysiologic interplay but also the incidence of both is expected to increase due to the demographic factors, aging and obesity.
AF is also a frequent comorbidity in patients with mitral valve regurgitation (MR) undergoing transcatheter edge-to-edge repair (TEER) with an incidence between 33-53% in randomized controlled trials. This is of particular clinical relevance due the complex and deleterious interaction between AF, MR, and left ventricular dysfunction. AF may pronounce left ventricular systolic dysfunction and enhance functional MR by mitral annulus dilatation (3). Current data has shown that AF contributes markedly to the course of functional MR and determines an unfavourable outcome. Catheter ablation (CA) for AF in the setting of congestive heart failure (CHF) has recently been demonstrated to be associated with a prognostic benefit in all stages of systolic left ventricular heart failure (heart failure with reduced ejection fraction, HFrEF). Although, the benefit of rhythm control in general, but also after surgical mitral valve repair (MVR) has been shown data in the setting of AF in TEER is sparse. In a recent multi-center observational cohort, the outcome of patients undergoing CA before or after TEER was investigated. As a proof of concept, it was shown that CA was associated with a prognostic benefit outweighing the negative influence of AF. Thus, the present study aims at investigating the prognostic relevance of CA following TEER in a randomized, prospective design.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 956 is above the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Atrial Fibrillation Network is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Usual Care
Other: Pulmonary Vein Isolation
Usual care will consist of optimal AF and heart failure therapy based on guideline recommendations and local protocols and usage. Individual treatment decisions will be taken by the site teams, considering the approved instruction for use (IFU) of medical devices and summary of product characteristics (SmPC) of all approved medications in patients with AF. The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
Patients randomised to AF ablation will undergo pulmonary vein isolation using a safe and effective technology within 30 days after randomisation.
Composite of cardiovascular complications related to AF
It is defined as the time from randomisation to the first occurrence of (1) a composite of cardiovascular death, ischemic stroke or systemic embolic event,hospitalisation for heart failure (MACCE) and/or (2) death of any cause in a hierarchical order.
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
The Primary Safety Outcomes are the occurrence of AF ablation associated serious adverse events, hemorrhagic stroke, and non-serious adverse events of special interest.
Serious Adverse Events (SAEs), including primary and secondary outcome parameters if based on clinical events, will be adjudicated by the independent Clinical Event Committee (CEC) according to standardised definitions given in the CEC charter.
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Time to individual components of first primary endpoint (MACCE)
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Time to ECG documented AF recurrence
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Time to ILR documented AF recurrence (AF burden sub-study)
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Time to any documented AF recurrence
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
AF burden assessed in the AF burden (ILR) sub-study
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Atrial arrhythmias assessed in the AF burden (ILR) sub-study
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Other arrhythmias assessed in the AF burden (ILR) sub-study
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Total number of ECG documented AF recurrences
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Quality of life changes at 12 and 24 months compared to baseline (assessed by KCCQ-12)
Time frame: From Enrollment to month 24.
Quality of life changes at 12 and 24 months compared to baseline (assessed by AFEQT)
Time frame: From Enrollment to month 24
Quality of life changes at 12 and 24 months compared to baseline (assessed by EQ-5D-5L)
Quality of life as assessed by the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-5D-5L): The resulting score of the UK index ranges from 1 (for the best state) to - 0.285 (for the worst state). EQ5D- VAS: visual-analogue scale (0 worst to 100 best).
Time frame: From Enrollment to month 24.
MoCA-test score changes at 12 months compared to baseline
Time frame: From Enrollment to month 12
Heart failure progression (pro-BNP) at 12 months compared to baseline
Time frame: From Enrollment to month 12.
Heart failure progression (NYHA) at 12 months compared to baseline
Time frame: From Enrollment to month 12
ECHO: LA size assessed at 12 months, and if available at 24 months and further yearly FU visits as changes to baseline
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
ECHO: LA volume assessed at 12 months, and if available at 24 months and further yearly FU visits as changes to baseline
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
ECHO: LV size assessed at 12 months, and if available at 24 months and further yearly FU visits as changes to baseline
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
ECHO: LV function assessed at 12 months, and if available at 24 months and further yearly FU visits as changes to baseline
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
ECHO: MR grading assessed at 12 months, and if available at 24 months and further yearly FU visits as changes to baseline
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Time to AF progression (documented as clinically evaluated)
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Time to AF regression (documented as clinically evaluated)
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Number of required re-M-TEER procedures over the entire follow-up duration
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Number of total ablations procedures over the entire follow-up duration
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Number of nights spent in hospital (per year)
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
Number of ablation procedures per patient (including the index ablation procedure in the early AF ablation group)
Time frame: Throughout study completion, estimated at a median follow-up period of 33 months.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atrial Fibrillation Network